Dean G. Brown

Jnana Therapeutics (United States) — United States

Computer Science · Physical Sciences

28h-index6.8kcitations102works4.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Computational Drug Discovery Methods(14), Receptor Mechanisms and Signaling(12), Pharmacogenetics and Drug Metabolism(8), Neuroscience and Neuropharmacology Research(7), Chemical Synthesis and Analysis(7)

Publications102 total

What Do Oral Drugs Really Look Like? Dose Regimen, Pharmacokinetics, and Safety of Recently Approved Small-Molecule Oral Drugs
Journal of Medicinal Chemistry·2025· 3 citedOpen Access
Current and Emerging Prodrug Strategies
Journal of Medicinal Chemistry·2025· 8 cited
Te Mātai Manawa A Whānau: Family Heart Echo Screening Study
Heart Lung and Circulation·2025Open Access
The Importance of Publishing for Industrial Medicinal Chemists
Journal of Medicinal Chemistry·2025· 1 cited
Opposing roles of p38α-mediated phosphorylation and PRMT1-mediated arginine methylation in driving TDP-43 proteinopathy
Cell Reports·2025· 1 citedOpen Access
Opposing roles of p38α-mediated phosphorylation and PRMT1-mediated arginine methylation in driving TDP-43 proteinopathy
Cell Reports·2025· 9 citedOpen Access
SLC6A19 inhibition facilitates urinary neutral amino acid excretion and lowers plasma phenylalanine
JCI Insight·2024· 8 citedOpen Access
Novel Corrector for Variants of SLC6A8: A Therapeutic Opportunity for Creatine Transporter Deficiency
UNC Libraries·2024Open Access
Novel Corrector for Variants of SLC6A8: A Therapeutic Opportunity for Creatine Transporter Deficiency
ACS Chemical Biology·2024· 7 citedOpen Access
Pharmacological inhibition of SLC6A19 lowers toxic phenylalanine burden in a PKU mouse model
Molecular Genetics and Metabolism·2024Open Access
JNT-517, a first-in-class SLC6A19 inhibitor for the treatment of phenylketonuria, enhances urinary excretion of phenylalanine in healthy volunteers
Molecular Genetics and Metabolism·2024· 2 cited
A Drug Discovery Perspective on FDA Expedited Development and Incentive Programs
Journal of Medicinal Chemistry·2024· 17 cited
Multidrug-Resistant Gram-Negative Bacteria in Burn Patients
UNC Libraries·2024Open Access
Fragment-Based Screening Identifies New Quinazolinone-Based Inositol Hexakisphosphate Kinase (IP6K) Inhibitors
ACS Medicinal Chemistry Letters·2023· 7 citedOpen Access
Adapting to the Changing Landscape of Biotech-Driven Drug Discovery
Journal of Medicinal Chemistry·2023· 3 cited
Correction to “An Analysis of Successful Hit-to-Clinical Candidate Pairs”
Journal of Medicinal Chemistry·2023
An Analysis of Successful Hit-to-Clinical Candidate Pairs
Journal of Medicinal Chemistry·2023· 41 citedOpen Access
A SMALL MOLECULE SLC6A19 INHIBITOR INCREASES URINARY PHENYLALANINE EXCRETION AND REDUCES ITS PATHOGENIC PLASMA ACCUMULATION IN A PHENYLKETONURIA MOUSE MODEL
Molecular Genetics and Metabolism·2023· 5 cited
Fast Neutron Evaluations for Advanced Lead Systems [Slides]
2023Open Access
Some Observations and Guidance on Perspectives in the <i>Journal of Medicinal Chemistry</i>
Journal of Medicinal Chemistry·2023· 1 cited
page 1 of 6Next →

Frequent Co-authors

Heike J. Wobst(7), Jonas Boström(6), Nicholas J. Brandon(5), Scott Throner(5), Niek Dekker(4), Stefan Geschwindner(3), Arjan Snijder(3), Linda Sundström(3), James Shorter(3), Valerie Hoesch(3), Linda A. Sygowski(3), Rebecca A. Urbanek(3), Gary B. Steelman(3), Clay W. Scott(3), Michael W. Wood(3), Jian Yu(3), Todd A. Brugel(3), Michael Balestra(3), Gerard M. Koether(3), Laura M. Panko(3)